Apellis Pharmaceuticals Inc (NASDAQ: APLS) kicked off on Friday, down -2.84% from the previous trading day, before settling in for the closing price of $20.04. Over the past 52 weeks, APLS has traded in a range of $16.10-$41.94.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 20.08% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -19.51%. With a float of $103.50 million, this company’s outstanding shares have now reached $125.66 million.
In an organization with 710 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 82.94%, operating margin of -24.0%, and the pretax margin is -28.66%.
Apellis Pharmaceuticals Inc (APLS) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Apellis Pharmaceuticals Inc is 17.70%, while institutional ownership is 100.03%. The most recent insider transaction that took place on Jul 17 ’25, was worth 398,735. In this transaction Chief Executive Officer of this company sold 19,725 shares at a rate of $20.21, taking the stock ownership to the 331,605 shares. Before that another transaction happened on Jul 16 ’25, when Company’s General Counsel sold 5,000 for $19.55, making the entire transaction worth $97,750. This insider now owns 128,730 shares in total.
Apellis Pharmaceuticals Inc (APLS) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -19.51% per share during the next fiscal year.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) Trading Performance Indicators
Take a look at Apellis Pharmaceuticals Inc’s (APLS) current performance indicators. Last quarter, stock had a quick ratio of 3.62. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.15.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.79, a number that is poised to hit -0.48 in the next quarter and is forecasted to reach -0.70 in one year’s time.
Technical Analysis of Apellis Pharmaceuticals Inc (APLS)
Let’s dig in a bit further. During the last 5-days, its volume was 1.55 million. That was inferior than the volume of 2.18 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 73.77%.
During the past 100 days, Apellis Pharmaceuticals Inc’s (APLS) raw stochastic average was set at 27.99%, which indicates a significant decrease from 67.15% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.85 in the past 14 days, which was lower than the 1.05 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $18.23, while its 200-day Moving Average is $25.02. However, in the short run, Apellis Pharmaceuticals Inc’s stock first resistance to watch stands at $20.19. Second resistance stands at $20.92. The third major resistance level sits at $21.40. If the price goes on to break the first support level at $18.99, it is likely to go to the next support level at $18.51. The third support level lies at $17.78 if the price breaches the second support level.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) Key Stats
The company with the Market Capitalisation of 2.45 billion has total of 125,682K Shares Outstanding. Its annual sales at the moment are 781,370 K in contrast with the sum of -197,880 K annual income. Company’s last quarter sales were recorded 166,800 K and last quarter income was -92,230 K.
